Genetically modified T lymphocytes can effectively recognize the molecule CS1, which is present in more than 95% of myeloma cells, and help the body's immune system eradicate the cells, according to researchers from the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The modified T cells can be reproduced in the lab and can potentially replicate in the body to stop tumor growth and prevent relapse for a greater period of time than current myeloma treatments. The study appeared in the journal Clinical Cancer Research.

Related Summaries